UBS Group’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-9,848
| Closed | -$3K | – | 10482 |
|
|
2022
Q3 | $3K | Sell |
9,848
-11,428
| -54% | -$3.48K | ﹤0.01% | 8566 |
|
|
2022
Q2 | $8K | Buy |
+21,276
| New | +$8K | ﹤0.01% | 7380 |
|
|
2022
Q1 | – | Sell |
-7,561
| Closed | -$17K | – | 10068 |
|
|
2021
Q4 | $17K | Sell |
7,561
-54,932
| -88% | -$124K | ﹤0.01% | 7002 |
|
|
2021
Q3 | $286K | Sell |
62,493
-2,601
| -4% | -$11.9K | ﹤0.01% | 4053 |
|
|
2021
Q2 | $289K | Buy |
65,094
+61,253
| +1,595% | +$272K | ﹤0.01% | 4099 |
|
|
2021
Q1 | $28K | Buy |
3,841
+766
| +25% | +$5.58K | ﹤0.01% | 6065 |
|
|
2020
Q4 | $23K | Buy |
3,075
+2,934
| +2,081% | +$21.9K | ﹤0.01% | 5843 |
|
|
2020
Q3 | $1K | Sell |
141
-3,737
| -96% | -$26.5K | ﹤0.01% | 6994 |
|
|
2020
Q2 | $33K | Sell |
3,878
-969
| -20% | -$8.25K | ﹤0.01% | 5369 |
|
|
2020
Q1 | $24K | Sell |
4,847
-5,486
| -53% | -$27.2K | ﹤0.01% | 5480 |
|
|
2019
Q4 | $74K | Buy |
10,333
+3,993
| +63% | +$28.6K | ﹤0.01% | 5113 |
|
|
2019
Q3 | $69K | Buy |
6,340
+4,839
| +322% | +$52.7K | ﹤0.01% | 5068 |
|
|
2019
Q2 | $20K | Buy |
1,501
+1,454
| +3,094% | +$19.4K | ﹤0.01% | 5753 |
|
|
2019
Q1 | $0 | Sell |
47
-2,956
| -98% | – | ﹤0.01% | 7247 |
|
|
2018
Q4 | $31K | Buy |
+3,003
| New | +$31K | ﹤0.01% | 5566 |
|